You just read:

CTI BioPharma Announces First Patient Enrolled in Phase 2 Trial of Pacritinib in Patients with Myelofibrosis who have Thrombocytopenia and who have been Previously Treated with Ruxolitinib

News provided by

CTI BioPharma Corp.

Aug 01, 2017, 01:30 ET